← All trials
NCT06792552
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 26, 2025
- Primary completion
- Feb 29, 2028
- Completion date
- Aug 31, 2028
- First posted
- Jan 24, 2025
- Last posted
- Nov 24, 2025
- Enrollment
- 414
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NextCure, Inc.Lead sponsor
- Shanghai Xianxiang Medical Technology Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.